{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:39:44Z","timestamp":1794037184302,"version":"4.8.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The Modified Vaccinia Ankara vaccine developed by Bavarian Nordic (MVA-BN) was widely deployed to prevent mpox during the 2022 global outbreak. This vaccine was initially approved for mpox based on its reported immunogenicity (from phase I\/II trials) and effectiveness in animal models, rather than evidence of clinical efficacy. However, no validated correlate of protection after vaccination has been identified. Here we performed a systematic search and meta-analysis of the available data to test whether vaccinia-binding ELISA endpoint titer is predictive of vaccine effectiveness against mpox. We observe a significant correlation between vaccine effectiveness and vaccinia-binding antibody titers, consistent with the existing assumption that antibody levels may be a correlate of protection. Combining this data with analysis of antibody kinetics after vaccination, we predict the durability of protection after vaccination and the impact of dose spacing. We find that delaying the second dose of MVA-BN vaccination will provide more durable protection and may be optimal in an outbreak with limited vaccine stock. Although further work is required to validate this correlate, this study provides a quantitative evidence-based approach for using antibody measurements to predict the effectiveness of mpox vaccination.<\/jats:p>","DOI":"10.1038\/s41467-024-48180-w","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T05:02:19Z","timestamp":1715144539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Predicting vaccine effectiveness for mpox"],"prefix":"10.1038","volume":"15","author":[{"given":"Matthew T.","family":"Berry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0772-6122","authenticated-orcid":false,"given":"Shanchita R.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7746-9649","authenticated-orcid":false,"given":"Timothy E.","family":"Schlub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Notaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohana","family":"Kunasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Grulich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Raina","family":"MacIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4751-1831","authenticated-orcid":false,"given":"Miles P.","family":"Davenport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2663-1551","authenticated-orcid":false,"given":"David S.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"key":"48180_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S1473-3099(03)00856-9","volume":"4","author":"DB Di Giulio","year":"2004","unstructured":"Di Giulio, D. B. & Eckburg, P. B. Human monkeypox: an emerging zoonosis. Lancet Infect. Dis. 4, 15\u201325 (2004).","journal-title":"Lancet Infect. Dis."},{"key":"48180_CR2","doi-asserted-by":"publisher","first-page":"e0007791","DOI":"10.1371\/journal.pntd.0007791","volume":"13","author":"EM Beer","year":"2019","unstructured":"Beer, E. M. & Rao, V. B. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLoS Negl. Trop. Dis. 13, e0007791 (2019).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"48180_CR3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3201\/eid2704.203569","volume":"27","author":"PY Nguyen","year":"2021","unstructured":"Nguyen, P. Y., Ajisegiri, W. S., Costantino, V., Chughtai, A. A. & MacIntyre, C. R. Reemergence of Human Monkeypox and Declining Population Immunity in the Context of Urbanization, Nigeria, 2017-2020. Emerg. Infect. Dis. 27, 1007\u20131014 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"48180_CR4","unstructured":"WHO Emergency Response Team. Multi-country outbreak of mpox, External situation report#29. (2023). https:\/\/www.who.int\/publications\/m\/item\/multi-country-outbreak-of-mpox-external-situation-report-29-20-october-2023."},{"key":"48180_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/ije\/17.3.643","volume":"17","author":"PE Fine","year":"1988","unstructured":"Fine, P. E., Jezek, Z., Grab, B. & Dixon, H. The transmission potential of monkeypox virus in human populations. Int. J. Epidemiol. 17, 643\u2013650 (1988).","journal-title":"Int. J. Epidemiol."},{"key":"48180_CR6","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/oxfordjournals.aje.a114328","volume":"123","author":"Z Jezek","year":"1986","unstructured":"Jezek, Z. et al. Four generations of probable person-to-person transmission of human monkeypox. Am. J. Epidemiol. 123, 1004\u20131012 (1986).","journal-title":"Am. J. Epidemiol."},{"key":"48180_CR7","first-page":"465","volume":"66","author":"Z Jezek","year":"1988","unstructured":"Jezek, Z., Grab, B., Szczeniowski, M. V., Paluku, K. M. & Mutombo, M. Human monkeypox: secondary attack rates. Bull. World Health Organ 66, 465\u2013470 (1988).","journal-title":"Bull. World Health Organ"},{"key":"48180_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/infdis\/154.4.551","volume":"154","author":"Z Jezek","year":"1986","unstructured":"Jezek, Z. et al. Human monkeypox: a study of 2,510 contacts of 214 patients. J. Infect. Dis. 154, 551\u2013555 (1986).","journal-title":"J. Infect. Dis."},{"key":"48180_CR9","doi-asserted-by":"publisher","first-page":"16262","DOI":"10.1073\/pnas.1005769107","volume":"107","author":"AW Rimoin","year":"2010","unstructured":"Rimoin, A. W. et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc. Natl Acad. Sci. USA 107, 16262\u201316267 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"48180_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.4269\/ajtmh.15-0168","volume":"93","author":"LD Nolen","year":"2015","unstructured":"Nolen, L. D. et al. Introduction of Monkeypox into a Community and Household: Risk Factors and Zoonotic Reservoirs in the Democratic Republic of the Congo. Am. J. Trop. Med. Hyg. 93, 410\u2013415 (2015).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"48180_CR11","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1093\/infdis\/jiab133","volume":"223","author":"ER Whitehouse","year":"2021","unstructured":"Whitehouse, E. R. et al. Clinical and epidemiological findings from enhanced monkeypox surveillance in Tshuapa province, democratic republic of the congo during 2011-2015. J. Infect. Dis. 223, 1870\u20131878 (2021).","journal-title":"J. Infect. Dis."},{"key":"48180_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jacc.2004.05.004","volume":"44","author":"RE Eckart","year":"2004","unstructured":"Eckart, R. E. et al. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J. Am. Coll. Cardiol. 44, 201\u2013205 (2004).","journal-title":"J. Am. Coll. Cardiol."},{"key":"48180_CR13","unstructured":"Summary Basis for Regulatory Action-Jynneos (US FDA, 2019); https:\/\/www.fda.gov\/media\/131802\/download."},{"key":"48180_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/nm1261","volume":"11","author":"Y Edghill-Smith","year":"2005","unstructured":"Edghill-Smith, Y. et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 11, 740\u2013747 (2005).","journal-title":"Nat. Med."},{"key":"48180_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.15585\/mmwr.mm7220a3","volume":"72","author":"AF Dalton","year":"2023","unstructured":"Dalton, A. F. et al. Estimated effectiveness of JYNNEOS vaccine in preventing Mpox: a multijurisdictional case-control study \u2014 United States, August 19, 2022\u2013March 31, 2023. Mmwr. Morbidity Mortal. Wkly. Rep. 72, 553\u2013558 (2023).","journal-title":"Mmwr. Morbidity Mortal. Wkly. Rep."},{"key":"48180_CR16","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1056\/NEJMoa2215201","volume":"388","author":"NP Deputy","year":"2023","unstructured":"Deputy, N. P. et al. Vaccine effectiveness of JYNNEOS against Mpox disease in the United States. N. Engl. J. Med. 388, 2434\u20132443 (2023).","journal-title":"N. Engl. J. Med."},{"key":"48180_CR17","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.15585\/mmwr.mm7149a5","volume":"71","author":"AB Payne","year":"2022","unstructured":"Payne, A. B. et al. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons-43 US Jurisdictions, July 31-October 1, 2022. Mmwr-Morbidity Mortal. Wkly. Rep. 71, 1560\u20131564 (2022).","journal-title":"Mmwr-Morbidity Mortal. Wkly. Rep."},{"key":"48180_CR18","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41591-023-02229-3","volume":"29","author":"Y Wolff Sagy","year":"2023","unstructured":"Wolff Sagy, Y. et al. Real-world effectiveness of a single dose of mpox vaccine in males. Nat. Med. 29, 748\u2013752 (2023).","journal-title":"Nat. Med."},{"key":"48180_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.15585\/mmwr.mm7220a4","volume":"72","author":"ES Rosenberg","year":"2023","unstructured":"Rosenberg, E. S. et al. Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection \u2014 New York, 2022. Mmwr. Morbidity Mortal. Wkly. Rep. 72, 559\u2013563 (2023).","journal-title":"Mmwr. Morbidity Mortal. Wkly. Rep."},{"key":"48180_CR20","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(23)00057-9","volume":"23","author":"M Bertran","year":"2023","unstructured":"Bertran, M. et al. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study. Lancet Infect. Dis. 23, 828\u2013835 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"48180_CR21","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.15585\/mmwr.mm7140e3","volume":"71","author":"AB Payne","year":"2022","unstructured":"Payne, A. B. et al. Incidence of Monkeypox Among Unvaccinated Persons Compared with Persons Receiving \u22651 JYNNEOS Vaccine Dose \u2014 32 U.S. Jurisdictions, July 31\u2013September 3, 2022. Mmwr. Morbidity Mortal. Wkly. Rep. 71, 1278\u20131282 (2022).","journal-title":"Mmwr. Morbidity Mortal. Wkly. Rep."},{"key":"48180_CR22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-022-02090-w","volume":"29","author":"LM Zaeck","year":"2023","unstructured":"Zaeck, L. M. et al. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat. Med. 29, 270\u2013278 (2023).","journal-title":"Nat. Med."},{"key":"48180_CR23","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/infdis\/jiab111","volume":"224","author":"SE Frey","year":"2021","unstructured":"Frey, S. E. et al. Human antibody responses following vaccinia immunization using protein microarrays and correlation with cell-mediated immunity and antibody-dependent cellular cytotoxicity responses. J. Infect. Dis. 224, 1372\u20131382 (2021).","journal-title":"J. Infect. Dis."},{"key":"48180_CR24","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.1016\/j.vaccine.2015.06.075","volume":"33","author":"SE Frey","year":"2015","unstructured":"Frey, S. E. et al. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naive subjects. Vaccine 33, 5225\u20135234 (2015).","journal-title":"Vaccine"},{"key":"48180_CR25","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.vaccine.2013.04.050","volume":"31","author":"SE Frey","year":"2013","unstructured":"Frey, S. E. et al. Safety and immunogenicity of IMVAMUNE(R) smallpox vaccine using different strategies for a post event scenario. Vaccine 31, 3025\u20133033 (2013).","journal-title":"Vaccine"},{"key":"48180_CR26","doi-asserted-by":"publisher","first-page":"e0157335","DOI":"10.1371\/journal.pone.0157335","volume":"11","author":"RN Greenberg","year":"2016","unstructured":"Greenberg, R. N. et al. A randomized, double-blind, placebo-controlled Phase II trial investigating the safety and immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN(R)) in 56-80-Year-Old Subjects. PLoS One 11, e0157335 (2016).","journal-title":"PLoS One"},{"key":"48180_CR27","doi-asserted-by":"publisher","first-page":"e0138348","DOI":"10.1371\/journal.pone.0138348","volume":"10","author":"RN Greenberg","year":"2015","unstructured":"Greenberg, R. N. et al. A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis. PLoS One 10, e0138348 (2015).","journal-title":"PLoS One"},{"key":"48180_CR28","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/infdis\/jiac455","volume":"227","author":"H Ilchmann","year":"2023","unstructured":"Ilchmann, H. et al. One- and two-dose vaccinations with modified vaccinia ankara-bavarian nordic induce durable b-cell memory responses comparable to replicating smallpox vaccines. J. Infect. Dis. 227, 1203\u20131213 (2023).","journal-title":"J. Infect. Dis."},{"key":"48180_CR29","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.vaccine.2017.02.032","volume":"35","author":"LA Jackson","year":"2017","unstructured":"Jackson, L. A. et al. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: a randomized clinical non-inferiority trial. Vaccine 35, 1675\u20131682 (2017).","journal-title":"Vaccine"},{"key":"48180_CR30","doi-asserted-by":"publisher","first-page":"e0195897","DOI":"10.1371\/journal.pone.0195897","volume":"13","author":"ET Overton","year":"2018","unstructured":"Overton, E. T. et al. Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: a randomised, double blind, placebo controlled phase III trial. PLoS One 13, e0195897 (2018).","journal-title":"PLoS One"},{"key":"48180_CR31","doi-asserted-by":"publisher","first-page":"ofv040","DOI":"10.1093\/ofid\/ofv040","volume":"2","author":"ET Overton","year":"2015","unstructured":"Overton, E. T. et al. Safety and immunogenicity of modified vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: an Open-Label, controlled clinical Phase II Trial. Open Forum Infect. Dis. 2, ofv040 (2015).","journal-title":"Open Forum Infect. Dis."},{"key":"48180_CR32","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","volume":"381","author":"PR Pittman","year":"2019","unstructured":"Pittman, P. R. et al. Phase 3 efficacy trial of modified vaccinia ankara as a vaccine against smallpox. N. Engl. J. Med. 381, 1897\u20131908 (2019).","journal-title":"N. Engl. J. Med."},{"key":"48180_CR33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.vaccine.2022.10.056","volume":"41","author":"E Overton","year":"2023","unstructured":"Overton, E. et al. A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN(R) vaccine in healthy adults. Vaccine 41, 397\u2013406 (2023).","journal-title":"Vaccine"},{"key":"48180_CR34","doi-asserted-by":"publisher","first-page":"e0122653","DOI":"10.1371\/journal.pone.0122653","volume":"10","author":"EM Zitzmann-Roth","year":"2015","unstructured":"Zitzmann-Roth, E. M. et al. Cardiac safety of modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study population. PLoS One 10, e0122653 (2015).","journal-title":"PLoS One"},{"key":"48180_CR35","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","volume":"28","author":"A von Krempelhuber","year":"2010","unstructured":"von Krempelhuber, A. et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 28, 1209\u20131216 (2010).","journal-title":"Vaccine"},{"key":"48180_CR36","unstructured":"Bavarian Nordic. A. Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN\u00ae) Smallpox Vaccine in Vaccinia-na\u00efve Healthy Subjects, https:\/\/clinicaltrials.gov\/study\/NCT01668537 (2020)."},{"key":"48180_CR37","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1056\/NEJMoa066092","volume":"357","author":"IJ Amanna","year":"2007","unstructured":"Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903\u20131915 (2007).","journal-title":"N. Engl. J. Med."},{"key":"48180_CR38","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"48180_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40204-1","volume":"14","author":"E Stadler","year":"2023","unstructured":"Stadler, E. et al. Monoclonal antibody levels and protection from COVID-19. Nat. Commun. 14, 4545 (2023).","journal-title":"Nat. Commun."},{"key":"48180_CR40","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881\u2013891 (2021).","journal-title":"Lancet"},{"key":"48180_CR41","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ijid.2023.03.005","volume":"130","author":"F Vairo","year":"2023","unstructured":"Vairo, F. et al. The possible effect of sociobehavioral factors and public health actions on the mpox epidemic slowdown. Int. J. Infect. Dis. 130, 83\u201385 (2023).","journal-title":"Int. J. Infect. Dis."},{"key":"48180_CR42","doi-asserted-by":"publisher","first-page":"342","DOI":"10.15585\/mmwr.mm7213a4","volume":"72","author":"LE Owens","year":"2023","unstructured":"Owens, L. E. et al. JYNNEOS Vaccination Coverage Among Persons at Risk for Mpox \u2014 United States, May 22, 2022\u2013January 31, 2023. Mmwr. Morbidity Mortal. Wkly. Rep. 72, 342\u2013347 (2023).","journal-title":"Mmwr. Morbidity Mortal. Wkly. Rep."},{"key":"48180_CR43","doi-asserted-by":"publisher","unstructured":"Azzi, A. Unusual Monkeypox virus outbreak in 2022: Phenotypic and molecular characteristics. Aspects of Mol. Med. 1 https:\/\/doi.org\/10.1016\/j.amolm.2023.100001 (2023).","DOI":"10.1016\/j.amolm.2023.100001"},{"key":"48180_CR44","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1126\/science.add4153","volume":"378","author":"CM Gigante","year":"2022","unstructured":"Gigante, C. M. et al. Multiple lineages of monkeypox virus detected in the United States, 2021\u20132022. Science 378, 560\u2013565 (2022).","journal-title":"Science"},{"key":"48180_CR45","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3201\/eid2903.221231","volume":"29","author":"I Sanz-Munoz","year":"2023","unstructured":"Sanz-Munoz, I. et al. Possible Mpox protection from smallpox vaccine-generated antibodies among older adults. Emerg. Infect. Dis. 29, 656\u2013658 (2023).","journal-title":"Emerg. Infect. Dis."},{"key":"48180_CR46","doi-asserted-by":"publisher","first-page":"e2006601","DOI":"10.1371\/journal.pbio.2006601","volume":"16","author":"A Antia","year":"2018","unstructured":"Antia, A. et al. Heterogeneity and longevity of antibody memory to viruses and vaccines. PLoS Biol. 16, e2006601 (2018).","journal-title":"PLoS Biol."},{"key":"48180_CR47","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nm1273","volume":"11","author":"E Hammarlund","year":"2005","unstructured":"Hammarlund, E. et al. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat. Med. 11, 1005\u20131011 (2005).","journal-title":"Nat. Med."},{"key":"48180_CR48","doi-asserted-by":"publisher","first-page":"e668","DOI":"10.1093\/milmed\/usz181","volume":"184","author":"MP Kunasekaran","year":"2019","unstructured":"Kunasekaran, M. P., Chen, X., Costantino, V., Chughtai, A. A. & MacIntyre, C. R. Evidence for residual immunity to smallpox after vaccination and implications for re-emergence. Mil. Med. 184, e668\u2013e679 (2019).","journal-title":"Mil. Med."},{"key":"48180_CR49","doi-asserted-by":"publisher","first-page":"104714","DOI":"10.1016\/j.idnow.2023.104714","volume":"53","author":"S Jamard","year":"2023","unstructured":"Jamard, S. et al. Resurgence of symptomatic Mpox among vaccinated patients: First clues from a new-onset local cluster. Infect. Dis. Now. 53, 104714 (2023).","journal-title":"Infect. Dis. Now."},{"key":"48180_CR50","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/aje\/kwg225","volume":"158","author":"M Eichner","year":"2003","unstructured":"Eichner, M. Analysis of historical data suggests long-lasting protective effects of smallpox vaccination. Am. J. Epidemiol. 158, 717\u2013723 (2003).","journal-title":"Am. J. Epidemiol."},{"key":"48180_CR51","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s15010-006-6603-5","volume":"34","author":"H Nishiura","year":"2006","unstructured":"Nishiura, H. & Eichner, M. Estimation of the duration of vaccine-induced residual protection against severe and fatal smallpox based on secondary vaccination failure. Infection 34, 241\u2013246 (2006).","journal-title":"Infection"},{"key":"48180_CR52","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/01.ede.0000229196.41862.c2","volume":"17","author":"H Nishiura","year":"2006","unstructured":"Nishiura, H., Schwehm, M. & Eichner, M. Still protected against smallpox? Estimation of the duration of vaccine-induced immunity against smallpox. Epidemiology 17, 576\u2013581 (2006).","journal-title":"Epidemiology"},{"key":"48180_CR53","doi-asserted-by":"publisher","first-page":"e0010141","DOI":"10.1371\/journal.pntd.0010141","volume":"16","author":"EM Bunge","year":"2022","unstructured":"Bunge, E. M. et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl. Trop. Dis. 16, e0010141 (2022).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"48180_CR54","unstructured":"WebPlotDigitizer v. 4.6. https:\/\/automeris.io\/WebPlotDigitizer (2022)."},{"key":"48180_CR55","unstructured":"RStan: The R interface to Stan v. 2.26.23.https:\/\/mc-stan.org\/ (2023)."},{"key":"48180_CR56","unstructured":"Stan Modeling Language Users Guide and Reference Manual v. 2.23.https:\/\/mc-stan.org (2023)."},{"key":"48180_CR57","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.vaccine.2013.02.053","volume":"31","author":"ML Jackson","year":"2013","unstructured":"Jackson, M. L. & Nelson, J. C. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 31, 2165\u20132168 (2013).","journal-title":"Vaccine"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48180-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48180-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48180-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T06:04:08Z","timestamp":1715148248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48180-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["48180"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-48180-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.11.23.23298850","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,8]]},"assertion":[{"value":"1 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.R.M. is on the WHO SAGE Working Group on Smallpox and Monkeypox. The authors have no other competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The analysis of publicly available de-identified clinical trial data, as performed in this study, was approved under the UNSW Sydney Human Research Ethics Committee (approval HC200242).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"3856"}}